MA27557A1 - Derives d'indolyle pyrazinone utiles pour le traitement des maladies et des troubles hyperproliferants associes a l'angiogenese - Google Patents
Derives d'indolyle pyrazinone utiles pour le traitement des maladies et des troubles hyperproliferants associes a l'angiogeneseInfo
- Publication number
- MA27557A1 MA27557A1 MA28322A MA28322A MA27557A1 MA 27557 A1 MA27557 A1 MA 27557A1 MA 28322 A MA28322 A MA 28322A MA 28322 A MA28322 A MA 28322A MA 27557 A1 MA27557 A1 MA 27557A1
- Authority
- MA
- Morocco
- Prior art keywords
- angiogenesis
- treatment
- disorders
- hyperproliferant
- indolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne un composé de formule (I) et son utilisation dans le traitement de troubles hyperprolifératifs et de maladies associées à l„angiogénès.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42549002P | 2002-11-12 | 2002-11-12 | |
US46091503P | 2003-04-07 | 2003-04-07 | |
US48420203P | 2003-06-30 | 2003-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27557A1 true MA27557A1 (fr) | 2005-10-03 |
Family
ID=32314888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28322A MA27557A1 (fr) | 2002-11-12 | 2005-06-09 | Derives d'indolyle pyrazinone utiles pour le traitement des maladies et des troubles hyperproliferants associes a l'angiogenese |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1565455A1 (fr) |
JP (1) | JP2006509840A (fr) |
KR (1) | KR20050072824A (fr) |
AR (1) | AR043059A1 (fr) |
AU (1) | AU2003290744A1 (fr) |
BR (1) | BR0316169A (fr) |
CA (1) | CA2505819A1 (fr) |
EC (1) | ECSP055851A (fr) |
HR (1) | HRP20050496A2 (fr) |
MA (1) | MA27557A1 (fr) |
MX (1) | MXPA05004779A (fr) |
NO (1) | NO20052796L (fr) |
PE (1) | PE20040832A1 (fr) |
PL (1) | PL376867A1 (fr) |
TW (1) | TW200418834A (fr) |
UY (1) | UY28074A1 (fr) |
WO (1) | WO2004043950A1 (fr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
WO2005049593A2 (fr) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | Promoteurs de l'apoptose contenant n-acylsulfonamide |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
WO2005054201A1 (fr) | 2003-11-20 | 2005-06-16 | Janssen Pharmaceutica N.V. | 2-quinolinones et 2-quinoxalinones substituees par 6-alcenyle et 6-phenylalkyle utilisees comme inhibiteurs de la poly(adp-ribose) polymerase (parp) |
EP1709011B1 (fr) | 2003-11-20 | 2015-07-29 | Janssen Pharmaceutica NV | 2-quinolinones et 2 quinoxalinones a substitution 7-phenylalkyl comme inhibiteurs de poly(adp-ribose) polymerase |
JP2007512331A (ja) * | 2003-11-21 | 2007-05-17 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 過剰増殖性疾患および血管新生に関連した病気の治療に有用なインドリル−チエノ’3,4−b!ピラジン−3−オン誘導体 |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
EA014955B1 (ru) | 2004-06-30 | 2011-04-29 | Янссен Фармацевтика Н. В. | Производные фталазина в качестве ингибиторов parp |
EA012416B1 (ru) | 2004-06-30 | 2009-10-30 | Янссен Фармацевтика Н.В. | Производные замещенного 2-алкилхиназолинона как ингибиторы parp |
US8080557B2 (en) | 2004-06-30 | 2011-12-20 | Janssen Pharmaceutica, Nv | Quinazolinedione derivatives as PARP inhibitors |
CN103524436B (zh) | 2004-11-17 | 2015-09-23 | 瑞恩药品公司 | 1-[(6,7-取代的烷氧基喹喔啉基)氨基羰基]-4-(杂)芳基哌嗪衍生物 |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
CA2606147C (fr) | 2005-05-12 | 2011-07-05 | Abbott Laboratories | Promoteurs d'apoptose |
US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Parpおよびtank阻害剤としてのキノリノン誘導体 |
RU2490260C2 (ru) | 2008-03-27 | 2013-08-20 | Янссен Фармацевтика Нв | Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина |
US20100113461A1 (en) | 2008-10-29 | 2010-05-06 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds |
WO2010074807A1 (fr) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | Dérivés 3, 4-dihydroquinolin-2 (1h) -one utilisés comme modulateurs de canaux sodiques |
CA2741537A1 (fr) * | 2008-11-07 | 2010-05-14 | Wyeth Llc | Modulateurs de lxr a base de quinoxaline |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
DK3122359T3 (da) | 2014-03-26 | 2021-03-08 | Astex Therapeutics Ltd | Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer |
CA2946130A1 (fr) * | 2014-04-18 | 2015-10-22 | Millennium Pharmaceuticals, Inc. | Composes a base de quinoxaline et leurs utilisations |
CN107438598A (zh) | 2015-01-20 | 2017-12-05 | 米伦纽姆医药公司 | 喹唑啉和喹啉化合物及其用途 |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
MX2018003564A (es) | 2015-09-23 | 2018-06-18 | Janssen Pharmaceutica Nv | 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer. |
AU2016328692B2 (en) | 2015-09-23 | 2021-03-11 | Janssen Pharmaceutica Nv | New compounds |
TW202317086A (zh) * | 2021-09-29 | 2023-05-01 | 加拿大商修復治療公司 | 化合物、醫藥組成物及製備化合物之方法及其使用方法 |
WO2024069592A1 (fr) * | 2022-09-29 | 2024-04-04 | Repare Therapeutics Inc. | Composés de n-([(l, 3,4-thiadiazolyle) substitué en position 5 ou (l,3-thiazolyl)](substitué)carboxamide, compositions pharmaceutiques et procédés de préparation de composés amides et leur utilisation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW472045B (en) * | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
WO1999042461A1 (fr) * | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Derives de quinoxaline substitues utilises comme antagonistes du recepteur de l'interleukine-8 |
-
2003
- 2003-11-05 AR ARP030104059A patent/AR043059A1/es unknown
- 2003-11-10 EP EP03783328A patent/EP1565455A1/fr not_active Withdrawn
- 2003-11-10 MX MXPA05004779A patent/MXPA05004779A/es not_active Application Discontinuation
- 2003-11-10 PL PL376867A patent/PL376867A1/pl unknown
- 2003-11-10 BR BR0316169-2A patent/BR0316169A/pt not_active Application Discontinuation
- 2003-11-10 KR KR1020057008396A patent/KR20050072824A/ko not_active Application Discontinuation
- 2003-11-10 CA CA002505819A patent/CA2505819A1/fr not_active Abandoned
- 2003-11-10 AU AU2003290744A patent/AU2003290744A1/en not_active Abandoned
- 2003-11-10 JP JP2005507146A patent/JP2006509840A/ja active Pending
- 2003-11-10 WO PCT/US2003/036003 patent/WO2004043950A1/fr active Application Filing
- 2003-11-11 TW TW092131443A patent/TW200418834A/zh unknown
- 2003-11-11 UY UY28074A patent/UY28074A1/es not_active Application Discontinuation
- 2003-11-11 PE PE2003001136A patent/PE20040832A1/es not_active Application Discontinuation
-
2005
- 2005-06-02 HR HR20050496A patent/HRP20050496A2/hr not_active Application Discontinuation
- 2005-06-09 NO NO20052796A patent/NO20052796L/no not_active Application Discontinuation
- 2005-06-09 MA MA28322A patent/MA27557A1/fr unknown
- 2005-06-10 EC EC2005005851A patent/ECSP055851A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20040832A1 (es) | 2005-01-27 |
KR20050072824A (ko) | 2005-07-12 |
UY28074A1 (es) | 2004-05-31 |
CA2505819A1 (fr) | 2004-05-27 |
WO2004043950A1 (fr) | 2004-05-27 |
AR043059A1 (es) | 2005-07-13 |
HRP20050496A2 (en) | 2006-06-30 |
EP1565455A1 (fr) | 2005-08-24 |
PL376867A1 (pl) | 2006-01-09 |
BR0316169A (pt) | 2005-09-27 |
NO20052796D0 (no) | 2005-06-09 |
MXPA05004779A (es) | 2005-07-22 |
TW200418834A (en) | 2004-10-01 |
AU2003290744A1 (en) | 2004-06-03 |
ECSP055851A (es) | 2005-09-20 |
NO20052796L (no) | 2005-06-09 |
JP2006509840A (ja) | 2006-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27557A1 (fr) | Derives d'indolyle pyrazinone utiles pour le traitement des maladies et des troubles hyperproliferants associes a l'angiogenese | |
MA29772B1 (fr) | Benzimidazoles substitues et procedes de preparation | |
MA27771A1 (fr) | 5,7-diaminopyrazolo[4,3-d]pyrimidines utiles dans le traitement de l'hypertension | |
DE60037597D1 (de) | Imidazol- Derivate | |
PT1337535E (pt) | Derivados de benzodiazepina | |
NO20032801L (no) | Tiazolderivater for behandling av PPAR-relaterte forstyrrelser | |
EA200300528A1 (ru) | 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6 | |
TNSN05045A1 (en) | Indole or benzimidazole derivatives for modulating ikappab kinase | |
TNSN02009A1 (fr) | Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant. | |
NO20063275L (no) | Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom | |
HRP20090281T1 (en) | 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases | |
EA200300716A1 (ru) | Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6 | |
MA27334A1 (fr) | Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur | |
ATE396186T1 (de) | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 | |
MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MXPA04005886A (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6. | |
MXPA04003087A (es) | Derivados de cromano como ligados de 5-hidroxitriptamina-6. | |
ATE304533T1 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
MA27549A1 (fr) | N-sulfonyl-4-methylene-amino-3-hydroxy-2-pyridones | |
SE9703414D0 (sv) | New compounds | |
ATE365730T1 (de) | Neuartige verbindungen | |
EA200301143A1 (ru) | Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
TNSN01175A1 (fr) | Derives de piperidines antagonistes selectives de sous- types de recepteurs de nmda, et compositions les contenant. | |
ATE301642T1 (de) | Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten |